This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

EPharmaSolutions And CenterWatch Partner To Improve Patient Eligibility And Access To Clinical Trials

CONSHOHOCKEN, Pa., March 21, 2013 /PRNewswire/ -- ePharmaSolutions, a leading clinical services and eClinical solutions provider, and CenterWatch, a top provider of clinical research business information and the leading online publisher of active clinical trial listings for patients and the public, are partnering to provide sponsors and patients with a novel solution that will increase the opportunities for patients to find trials for which they may qualify.

Only 5% of patients who respond to a specific patient recruitment advertisement ever end up participating, for one reason or another.   This is very discouraging for those patients who are highly motivated to gain access to experimental treatments through clinical trials.    Until now, 95% of patients who responded to a recruitment advertisement but were ineligible to participate are ever introduced to other studies for which they might qualify. ePharmaSolutions and CenterWatch, along with a consortium of the largest pharmaceutical companies and contract research organizations in the world, are aiming to change that through a collaborative effort called the 'Referral Plus' Initiative.  

The Referral Plus Initiative uses a proprietary technology platform developed by ePharmaSolutions that programmatically matches patients who screen and disqualify from one trial into other "like" studies using a geo-therapeutic matching algorithm that links the patients' screening responses to entry criteria of the studies listed on the platform in real time.   Patients who are not matched to active studies are invited to register with PatientLiveā„¢, a Microsoft based application that provides patients with personalized information about approved medications, new medical therapies and new clinical trial opportunities for their condition(s) provided by CenterWatch and hosted in Microsoft HealthVault. 

For pharmaceutical companies, Referral Plus helps optimize the millions of dollars spent on patient recruitment advertising while providing patients who respond to those advertisements with better chances to find studies for which they may qualify.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs